Barinthus Biotherapeutics Plc ADR (BRNS)
0.7600 unch (unch) 13:43 ET [NASDAQ]
0.7600 x 43 0.8920 x 2
Realtime by (Cboe BZX)
0.7600 x 43 0.8920 x 2
Realtime - - (-) -
for Thu, Apr 3rd, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -61,183 | -73,447 | 5,321 | -51,112 | -17,933 |
Depreciation Amortization | 5,800 | 5,429 | 4,323 | 602 | 208 |
Income taxes - deferred | -44 | -3,075 | -4,337 | -119 | N/A |
Accounts receivable | N/A | 5,800 | -5,833 | 559 | 479 |
Accounts payable and accrued liabilities | 898 | -3,378 | 1,140 | -3,528 | 586 |
Other Working Capital | 2,601 | 6,171 | -5,524 | -7,178 | 1,922 |
Other Operating Activity | 22,988 | 11,575 | -9,521 | 28,193 | 3,710 |
Operating Cash Flow | $-28,940 | $-50,925 | $-14,431 | $-32,583 | $-11,028 |
Cash Flows From Investing Activities | |||||
PPE Investments | -892 | -5,413 | -5,750 | -1,146 | -293 |
Net Acquisitions | N/A | N/A | N/A | -11,766 | N/A |
Investing Cash Flow | $-892 | $-5,413 | $-5,750 | $-12,912 | $-293 |
Cash Flows From Financing Activities | |||||
Debt Issued | N/A | N/A | N/A | N/A | 41,241 |
Debt Repayment | N/A | N/A | -159 | N/A | N/A |
Common Stock Issued | 2,163 | 2,035 | 484 | 228,013 | N/A |
Other Financing Activity | 0 | -163 | 0 | -5,271 | 194 |
Financing Cash Flow | $2,163 | $1,872 | $325 | $222,742 | $41,435 |
Exchange Rate Effect | -2,021 | 2,171 | 187 | -6,459 | 1,720 |
Beginning Cash Position | 142,090 | 194,385 | 214,054 | 43,266 | 11,432 |
End Cash Position | 112,400 | 142,090 | 194,385 | 214,054 | 43,266 |
Net Cash Flow | $-29,690 | $-52,295 | $-19,669 | $170,788 | $31,834 |
Free Cash Flow | |||||
Operating Cash Flow | -28,940 | -50,925 | -14,431 | -32,583 | -11,028 |
Capital Expenditure | -892 | -5,413 | -6,138 | -1,146 | -293 |
Free Cash Flow | -29,832 | -56,338 | -20,569 | -33,729 | -11,321 |